Medexus Pharmaceuticals Inc.

MDP.TOTSXHealthcare● Active

$3.95

+$0.04(+1.02%)

Market Cap$127586501

P/E Ratio—

52W High$4.17

52W Low$2.47

Avg Volume51K

Open$3.86

Beta1.84

Free Cash Flow Financials Revenue

Medexus Pharmaceuticals Inc. (MDP.TO) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

MDP.TO · free cash flow · updated Jun 9, 2026

Core FCF metrics

MDP.TO · FCF · TTM · margin & CAGR

Free cash flow was $21.3M for FY2025 (fiscal year ending 2025-03-31), up 15.5% year-over-year The FCF margin was 19.7%.

FY2025 Free Cash Flow$21.3M▲ +15.5% YoY

Trailing 12M (TTM)$17.2Mtrailing 4 quarters sum

FCF Margin19.7%$21.3M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

MDP.TO · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$24.0M(3M)$21.3M▲ +15.5%19.7%

FY2024$18.7M(0M)$18.4M▲ +1121.5%16.3%

FY2023−$1.4M(0M)−$1.8M▲ +79.7%-1.7%

FY2022−$1.2M(8M)−$8.9M▼ 55.6%-11.6%

FY2021$5.0M(11M)−$5.7M▼ 61.7%-7.2%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

MDP.TO · P/FCF · FCF yield · FCF per share

Medexus Pharmaceuticals Inc. (MDP.TO) trades at a FCF yield of 18.77% and a price-to-free-cash-flow ratio of 6.0x. FCF per share stands at $0.66, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

18.77%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$0.66

TTM FCF ÷ Shares Outstanding

Price / FCF

x6.0

Share Price ÷ FCF per Share

EV / FCF (TTM)

x5.9

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-03-31

Cash flow statement summary

MDP.TO · cash flow statement · operating / investing / financing

For FY2025, Medexus Pharmaceuticals Inc. generated $24.0M in operating cash flow and spent 3M in capital expenditures, yielding $21.3M in free cash flow.

Operating Activities

+$24.0M

Cash from core business operations

2025-03-31

Investing Activities

−$6.0M

CapEx, acquisitions & investments

2025-03-31

Financing Activities

+$0.8M

Buybacks, dividends & debt

2025-03-31

FCF FormulaOperating CF ($24.0M) − |CapEx| (3M) = FCF ($21.3M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

MDP.TO vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Medexus Pharmaceuticals Inc.YOU

MDP.TO

$21.3M+15.5%19.7%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Medexus Pharmaceuticals Inc. (MDP.TO) reported free cash flow of $21.3M for FY2025 (fiscal year ending 2025-03-31), up 15.5% year-over-year. The FCF margin was 19.7%.

Based on available data, Medexus Pharmaceuticals Inc. has maintained positive free cash flow for at least 2 fiscal year(s). FCF peaked at $21.3M in FY2025.

Medexus Pharmaceuticals Inc.'s FCF yield is 18.77% and price-to-FCF ratio is 6.0x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

MDP.TO free cash flow · 8 questions

Medexus Pharmaceuticals Inc. free cash flow was $21.3M for FY2025, up 15.5% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $17.2M.

MDP.TO free cash flowMDP.TO FCFMDP.TO FCF 2025MDP.TO free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Medexus Pharmaceuticals Inc. · Medexus Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026